clinical trial · NCT07579910
Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B)
MPS IIIBTralesinidase alfa (TA)
brief summary
The primary objectives of this study are to evaluate the effects of Tralesinidase Alfa (TA) on cognition
started
Dec 1, 2026
primary completion
Aug 1, 2033
completion
Aug 1, 2033
last updated
Sep 21, 2026
official title
A Phase 3, Randomized, Single-blind, Parallel Group, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebroventricular Tralesinidase Alfa Treatment Compared to Standard of Care in Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol